By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Melanomas are discussed in a new report. According to news originating from Liaoning, People's Republic of China, by NewsRx correspondents, research stated, "A dilemma for current cancer therapy is surgical injury in addition to the toxicities and inefficiencies of systemic chemotherapy. Meanwhile, localized therapies have become a noticeable strategy."
Our news journalists obtained a quote from the research from Shenyang Pharmaceutical University, "In this study, Cucurbitacin (Cuc)-loaded poly(lactic-co-glycolic acid) particles of different sizes (about 50 m, 5 m, and 270 nm, respectively) were prepared as the sustained-release system for intratumoral injection, and their physicochemical properties, in vitro cytotoxicity, particles-cells interactions, pharmacokinetics, and pharmacodynamics were systemically investigated for the first time. The results of cytotoxicity experiments and pharmacokinetic/pharmacodynamic studies indicated that the release patterns of the particles would strongly affect the biological efficiency not only at the cell level but also in two types of animal models. Cuc raw material and nanoparticles showed higher initial burst release in vitro, and higher drug concentration in tumor and plasma. Large particles (about 50 m) showed lower initial burst and slow drug release, which would not supply enough amount of drug to inhibit the cancer cell growth during the whole treatment period. Particles with mean diameter of about 5 m performed the best anti-melanoma efficiency both in vitro and in vivo."
According to the news editors, the research concluded: "The release patterns, instead of the particles-cells interactions, would be the key factors to affect the biological effects of the particulate system for intratumoral injection."
For more information on this research see: The anti-melanoma efficiency of the intratumoral injection of cucurbitacin-loaded sustained-release carriers: A PLGA particle system. Journal of Pharmaceutical Sciences, 2013;102(8):2550-2563. Journal of Pharmaceutical Sciences can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Journal of Pharmaceutical Sciences - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1520-6017)
The news correspondents report that additional information may be obtained from J.B. Guo, Shenyang Pharmaceutical University, Sch Life Sci & Biopharmaceut, Shenyang 110016, Liaoning, People's Republic of China. Additional authors for this research include X. Li, H.D. Yu, Z.H. Tang, X. Tang, C.C. Cai, J.H. Xu and H. Xu (see also Melanomas).
Keywords for this news article include: Asia, Drugs, Liaoning, Melanomas, Triterpenes, Chemotherapy, Cucurbitacins, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC